Home » Merck KGaA Pulls European Filing, Sacks Erbitux Lung Cancer Development
Merck KGaA Pulls European Filing, Sacks Erbitux Lung Cancer Development
Merck KGaA has withdrawn its EU marketing application for a lung cancer indication for its cancer drug Erbitux after regulatory authorities requested more clinical data. The company will no longer pursue a non-small cell lung cancer (NSCLC) indication, spokeswoman Phyllis Carter said.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May